Biora Therapeutics, Inc. Common Stock
BIOR
BIOR was delisted on the 10th of December, 2024.
30 hedge funds and large institutions have $13.2M invested in Biora Therapeutics, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 6 reducing their positions, and 6 closing their positions.
1,072% more call options, than puts
Call options by funds: $4.6M | Put options by funds: $392K
105% more capital invested
Capital invested by funds: $6.46M → $13.2M (+$6.79M)
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
50% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 6
0% more funds holding
Funds holding: 30 → 30 (0)
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$2.18M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$1.7M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$130K |
| 4 |
State Street
Boston,
Massachusetts
|
+$54.7K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$22K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$67.3K |
| 2 |
CF
Cantor Fitzgerald
New York
|
-$45.4K |
| 3 |
Group One Trading
Chicago,
Illinois
|
-$35.8K |
| 4 |
VF
Virtu Financial
New York
|
-$29K |
| 5 |
JP Morgan Chase
New York
|
-$6K |
BIOR Hedge Fund Activity: Q2 2023 in Review
30 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Biora Therapeutics, Inc. Common Stock (BIOR) for Q2 2023, worth a combined $13.2M — up 105% from $6.46M a quarter earlier.
Fund positioning in BIOR was balanced in Q2 2023: 6 funds opened new positions, 6 closed out, 9 added to existing stakes and 6 trimmed.
The largest buyer was Anson Funds Management, opening a new position worth an estimated $2.18M. The largest seller was GSA Capital Partners, cutting an estimated $67.3K.
- 30 institutional investors held Biora Therapeutics, Inc. Common Stock (BIOR) as of Q2 2023, unchanged from Q1 2023.
- Funds reported $13.2M of Biora Therapeutics, Inc. Common Stock stock for Q2 2023, up 105% quarter-over-quarter.
- 6 funds opened new Biora Therapeutics, Inc. Common Stock positions in Q2 2023 and 6 closed out, a net change of 0 holders.
- The largest Biora Therapeutics, Inc. Common Stock buyer in Q2 2023 was Anson Funds Management, an estimated $2.18M added.
- The largest Biora Therapeutics, Inc. Common Stock seller in Q2 2023 was GSA Capital Partners, an estimated $67.3K sold.
Based on aggregated 13F filings for Q2 2023.